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diagnosis of several pulmonary disorders [6], they
should be performed only after other diagnostic
procedures, e.g., bronchoalveolar lavage. In our
experience, lung biopsies are rarely performed as
the ﬁrst-choice procedure for diagnosis of deep
mycosis.
PCR ampliﬁcation of DNA from both mycelia
and spherules showed a single ampliﬁcation
product of c. 340 bp. A BLAST search showed
homology only for Coccidioides spp. sequences,
which suggests that amplicon sequencing is
not necessary for routine diagnostic purposes.
However, further studies with more patients
are required to evaluate the sensitivity of the
present protocol. In the protocol described by
Burt et al. [7], ﬁlamentous cultures of Coccidioides
spp. were grown in broth medium and then
inactivated by heating, followed by freezing in
liquid nitrogen and lyophilisation before extrac-
tion of DNA. The present study used an alternat-
ive method for safe DNA extraction from
ﬁlamentous cultures growing on solid media.
This protocol may be performed directly on
suspicious cultures grown from clinical material,
thereby reducing the time required to obtain
deﬁnitive diagnostic results.
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ABSTRACT
MacConkey agar containing either cefotaxime
1.0 mg ⁄L or ceftazidime 1.0 mg ⁄L was evaluated
for use in screening for extended-spectrum
b-lactamase (ESBL)-producing organisms. The
media were evaluated using known ESBL-posit-
ive and -negative strains and 630 clinical
specimens over a 6-month period. All Entero-
bacteriaceae isolated were identiﬁed and screened
for ESBL production by phenotypic methods.
In total, 14 ESBL-producing organisms were
detected in the clinical samples. All known
ESBL-positive strains were also detected. The
use of both screening plates was required to
detect all ESBLs.
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Detection of organisms producing an extended-
spectrum b-lactamase (ESBL) is not always easy
with routine susceptibility testing [1–3], and
delays in recognition, resulting in unsuitable
treatment with cephalosporins of severe infec-
tions caused by ESBL producers, has been linked
with a rise in the mortality rate [4]. There is a need
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for a sensitive and simple screening procedure to
enhance the detection of ESBL-producing bacteria
[5]. Ideally, use of a screening agar would allow
the initial isolation and recognition of potential
ESBL-producing organisms. Thus, previous
studies have attempted to develop screening
agars containing a single cephalosporin, either
cefotaxime or ceftazidime [6,7].
The present study evaluated the use of
two screening agars in combination to detect
ESBL-producing strains isolated from intensive
care unit (ICU) patients in Forth Valley Acute
Hospitals, Scotland. In total, 40 ESBL-positive
isolates, consisting of 16 strains producing known
ESBL enzyme types and 24 ESBL producers
(phenotypically determined) from clinical sam-
ples, and 50 negative controls, comprising known
b-lactamase-positive but non-ESBL-producing
clinical isolates, were used in the primary evalu-
ation of the media. In addition, Escherichia coli
ATCC25922 was used as a negative ESBL control,
and Klebsiella pneumoniae ATCC 700603 was used
as a positive ESBL control. For the clinical
evaluation, 630 routine samples were collected
from the ICUs of Forth Valley Acute Hospitals
over a 6-month period; these consisted of urines
(n = 192), tracheal aspirates (n = 122), groin
swabs (n = 200), wound swabs (n = 106) and
faeces (n = 10).
Mac X medium consisted of MacConkey agar
(Oxoid, Basingstoke, UK) supplemented with
cefotaxime sodium (Hoechst Marion Roussel,
Bridgewater, NJ, USA) 1.0 mg ⁄L. Mac Z medium
consisted of MacConkey agar supplemented with
ceftazidime pentahydrate (GlaxoSmithKline,
Brentford, UK) 1.0 mg ⁄L. MacConkey agar was
prepared according to the manufacturer’s instruc-
tions; the corresponding antibiotic solutions were
ﬁlter-sterilised and added aseptically following
sterilisation of the agar.
Each clinical sample and all controls were
inoculated on a MacConkey agar control plate,
Mac X andMac Z. All Enterobacteriaceae growing
on the control plate were identiﬁed using the
API 10S system (bioMe´rieux, Marcy l’Etoile,
France) and were tested for ESBL production.
Any organism growing on the two antibiotic-
containing test plateswas identiﬁed by theAPI 10S
system and the VITEK 2 system (bioMe´rieux). This
allowed comparisons with the test agars, as the
growth on the control plate reﬂected the overall
ﬂora of the subject, including any ESBL-producing
organisms. Isolates and controls were screened
for ESBL production by the Jarlier synergy test [8]
and a combination disk method (Oxoid). The
sensitivities and speciﬁcities (with 95% CIs) of
the two screening agars were calculated.
All 50 negative controls grew on the control
MacConkey plate, but were inhibited from grow-
ing on the two antibiotic-containing plates. The
growth of organisms producing known ESBLs is
summarised in Table 1. All of the positive con-
trols were detected by the Jarlier test. In total, 120
Table 1. Growth of organisms producing known exten-
ded-spectrum b-lactamases (ESBLs) on MacConkey agar
containing cefotaxime or ceftazidime
ESBL
Mac X
(cefotaxime 1.0 mg ⁄L)
Mac Z
(ceftazidime 1.0 mg ⁄L)
SHV-2 + +
SHV-3 – +
SHV-4 – +
SHV-5 + +
SHV-6 – +
TEM-3 + +
TEM-6 + +
TEM-7 – +
TEM-8 + +
TEM-10 – +
TEM-12 – +
TEM-16 + +
TEM-17 – +
TEM-24 + +
TEM-26 + +
CTX M-15 + –
+, presence of growth; –, absence of growth.
Table 2. Identity and number of clinical isolates grown
from clinical specimens on screening plates
Specimen type Organisms (n) ESBL-positive (n)
Urine Escherichia coli (2)
Klebsiella oxytoca (1)
Enterobacter cloacae (2) 2
Endotracheal aspirates Klebsiella pneumoniae (5) 4
Enterobacter cloacae (1)
Pseudomonas spp. (22)
Groin swabs Escherichia coli (22)
Klebsiella oxytoca (5)
Klebsiella pneumoniae (7) 6
Hafnia alvei (1)
Stenotrophomonas maltophilia (1)
Serratia liquefaciens (1)
Proteus mirabilis (2)
Enterobacter cloacae (1)
Enterobacter aerogenes (2)
Citrobacter koserii (1)
Citrobacter freundii (1) 1
Pseudomonas spp. (10)
Wound swabs Escherichia coli (13)
Klebsiella oxytoca (7) 1
Morganella morganii (1)
Acinetobacter baumanii (1)
Enterobacter cloacae (1)
Enterobacter aerogenes (1)
Pseudomonas spp. (3)
Faeces Escherichia coli (3)
Klebsiella oxytoca (1)
Pseudomonas spp. (2)
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isolates from clinical specimens grew on the
screening agars (Table 2), including 14 probable
ESBL-producing organisms. Apart from two
isolates of Enterobacter cloacae, all of these pre-
sumptive ESBL producers showed enhanced
resistance to cefotaxime and ceftazidime using
the Jarlier test, and demonstrated a ‡5 mm
increase in zone diameters using the combination
disk test for the cephalosporins plus clavulanic
acid; the two Ent. cloacae isolates gave a negative
result in the combination disk test. No ESBL-
producing organisms grew only on the MacCon-
key control plate.
An initial screening test to facilitate the detec-
tion of ESBL-producing bacteria in a clinical
setting is important not only for guiding treat-
ment, but also for early implementation of appro-
priate infection control measures. In the present
study, the combined use of MacConkey screening
agars supplemented with either ceftazidime or
cefoxatime enabled 100% detection of known
ESBL producers. It is important to note that the
use of these agars is primarily to facilitate the
isolation of potential ESBL producers, and any
growth on the plates should not be taken as
deﬁnitive proof of ESBL production, which can
only be achieved by use of appropriate conﬁrm-
atory tests. The selective plates will allow the
growth of any organism that has resistance to the
antibiotic incorporated in the agar. A recent study
has reported that this is a drawback [9], but
a compensating beneﬁt is that the agars may
also isolate organisms that hyperproduce AmpC
enzymes, and it is clearly advantageous to know
whether ICU patients are colonised by these
organisms. Any growth on the selective agars
can also be tested for resistance mechanisms
other than ESBL production.
The ESBL-producing isolates from clinical spec-
imens that were detected in this study grew on
cefotaxime and ceftazidime concentrations of
1.0 mg ⁄L in the Mac X and Mac Z screening
plates. Previous studies have used a range of
concentrations (0.5–2 mg ⁄L) of cefoxatime and
ceftazidime to facilitate the isolation of ESBL-
producing organisms [6,7]. However, variations
in the efﬁciency of detection of ESBL-producing
organisms with a single selective antibiotic have
been shown [6], and it is therefore unlikely that a
single selective medium will detect all known
ESBL producers [10].
In conclusion, it is suggested that two screening
plates, one containing cefotaxime 1.0 mg ⁄L and
one containing ceftazidime 1.0 mg ⁄L, can be used
to screen for ESBL-producing organisms. Such a
screening method would provide a quick and
easy-to-use method for detecting ESBL-producing
organisms in ICUs and elsewhere in hospitals,
and could therefore form a useful adjunct to
hospital infection control measures.
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